drugset
drugset / Trial / NCT01889160

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

NCT01889160 ↗

Phase 1 Completed 44 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

Study to investigate the safety profile of AZD4721 after single doses at different dose levels

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator VIMNERIXIN Small molecule — Oral

Indications

No indication recorded.